Additionally, when used in combination with a glioma vaccine of irradiated glioma cell lines expressing granulocyte macrophage-colony stimulating factor (GM-CSF), there was improved survival and increased levels of IFN-γ production compared to treatment with CTLA-4 blocking mAb alone [57]. The gene discussed is CSF2; the disease is glioma.